While most GIST carry activating mutations in KIT or PDGFRA (52), our study focuses on a rare subset, sdGIST, lacking mutations in KIT or PDGFRA, which are resistant to imatinib and found in younger patients. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.